Medical Xpress

MARCH 6, 2023

This also happens in our body, in driving an immune response. Like human drivers, antibodies have a "foot"—a sort of molecular limb that "presses" the gas and brake pedals. And as far as these cancer-fighting antibodies are concerned, speed is of the essence.

Immune Response 68

Immune Response Antibody 68

pharmaphorum

SEPTEMBER 7, 2020

A trial of Russia’s Sputnik V coronavirus vaccine has shown the jab produces an immune response, although the study was too small to produce conclusive findings, particularly on safety. All participants in the phase 2 trials (40 participants) produced antibodies against the SARS-CoV-2 spike protein.

Immune Response 107

Immune Response Vaccine Vaccination Trials 107

pharmaphorum

SEPTEMBER 30, 2020

Regeneron’s antibody cocktail seems to reduce levels of coronavirus and improve symptoms in patients, according to early test results. REGN-COV2 is a combination of two monoclonal antibodies and was designed to block infectivity of SARS-CoV-2 , the virus that causes COVID-19.

Antibody 135

Antibody Immune Response Trials Protein 135

Pharmaceutical Technology

FEBRUARY 6, 2023

Led by Feinstein Institutes researcher Haichao Wang, the new study focuses on detecting protein mediators that might contribute to uncontrolled immune responses to lethal infections. It explores the monoclonal antibody detection that may work against procathepsin-L (pCTS-L), a pro-inflammatory protein mediator, as the potential remedy.

Protein 264

Protein Research Antibody Immune Response 264

Pharmaceutical Technology

APRIL 10, 2023

It will also be used for the treatment of people who are not likely to have an adequate immune response to Covid-19 vaccination or for people who are not recommended for Covid-19 vaccination. Evusheld (formerly AZD7442) is a combination of two long-acting antibodies, tixagevimab (AZD8895) and cilgavimab (AZD1061).

Immune Response 265

Immune Response Antibody Vaccine Vaccination 265

Pharmaceutical Technology

APRIL 15, 2024

Discover how Atrium Health's groundbreaking patent revolutionizes cancer treatment with targeted antibodies and cytotoxic cells, enhancing immune response and improving patient outcomes.

Antibody 100

Antibody Immune Response Engineer 100

Pharmaceutical Technology

MAY 22, 2023

SM17 is a humanised IgG4-k monoclonal antibody that targets IL-17RB to treat asthma, idiopathic pulmonary fibrosis (IPF), atopic dermatitis (AD) and other immunological disorders. It can suppress Th2 immune responses by binding to IL-17RB on Type 2 innate lymphoid cells (ILC2s).

Immune Response 274

Immune Response Clinical Trials Clinical Trials Antibody 274

Pharmaceutical Technology

JUNE 28, 2022

Astellas Pharma and Sutro Biopharma have entered a global, strategic partnership and licencing agreement to discover and develop new immunostimulatory antibody-drug conjugates (iADCs). An iADC merges an antibody with a small molecule compound that elicits immunogenic cell death, and an immune-activating molecule.

Development 265

Development Antibody Immune Response Production 265

Medical Xpress

DECEMBER 6, 2022

Nearly three years into the pandemic, many of us now carry antibodies against the virus—due to an infection or two, a few doses of mRNA vaccine, or a round of monoclonal-antibody treatment.

Antibody 97

Antibody Vaccine Vaccination Immune Response 97

Medical Xpress

JANUARY 17, 2023

Formed after exposure to a pathogen or vaccine, germinal centers act as a kind of immune system training academy, helping B cells refine their response to the threat.

Immune Response 103

Immune Response Vaccine Vaccination Antibody 103

Medical Xpress

JANUARY 4, 2023

In a new study by researchers from Mass General Brigham's founding members, Brigham and Women's Hospital and Massachusetts General Hospital, a team extensively investigated the immune response of 16 adolescents and young adults who developed myocarditis after receipt of the COVID mRNA vaccine.

Immune Response 81

Immune Response Protein Vaccine Vaccination 81

BioSpace

AUGUST 13, 2020

A COVID-19 vaccine candidate developed by Chinese pharmaceutical company Sinopharm triggered antibody-based immune responses in early and mid-stage trials.

Immune Response 132

Immune Response Vaccine Vaccination Antibody 132

pharmaphorum

OCTOBER 5, 2021

AstraZeneca has sought emergency use authorisation for its antibody combination AZD7442, following trial results indicating it can prevent symptomatic COVID-19 infection when given to healthy patients. The post AZ files for emergency use of COVID-19 antibody combo in US appeared first on. Initial results from that study were negative.

Antibody 111

Antibody Immune Response Vaccine Vaccination 111

Scienmag

JULY 8, 2022

Researchers at the University of Southampton have gained unprecedented new insight into the key properties of an antibody needed to fight off cancer. The interdisciplinary study, published in Science Immunology, revealed how changing the flexibility of the antibody could stimulate a stronger immune response.

Antibody 86

Antibody Immune Response Scientist Research 86

BioSpace

SEPTEMBER 1, 2020

There is new research out of Iceland that suggests the body’s immune response to COVID-19 lasts longer than other research has suggested.

Immune Response 113

Immune Response Antibody Research 113

pharmaphorum

JANUARY 13, 2022

Preliminary data from an ongoing trial of AstraZeneca’s COVID-19 vaccine Vaxzevria has shown that a booster dose stimulates an increase in antibodies against Omicron, as well as other variants of the virus, including Alpha, Beta, Delta, and Gamma.

Antibody 98

Antibody Immune Response Vaccine Vaccination 98

XTalks

NOVEMBER 12, 2024

Thus, to address drug-resistant infections, pharma and biotech companies are developing novel treatments such as bacteriophage therapies, immunomodulators and monoclonal antibodies. Monoclonal Antibody Therapies Monoclonal antibodies are gaining traction as targeted treatments for bacterial and viral infections.

Bacteria 110

Bacteria Life Science Vaccine Vaccination 110

pharmaphorum

NOVEMBER 8, 2021

A single dose of the COVID-19 monoclonal antibody therapy developing Regeneron reduced the risk of contracting the virus by around 82% for up to eight months, according to new trial data. The post One dose of Regeneron’s COVID antibody protects for eight months appeared first on.

Antibody 105

Antibody Vaccine Vaccination Immune Response 105

BioSpace

SEPTEMBER 27, 2020

The company posted an interim analysis of its Phase I/IIa trial that showed a single dose of JNJ-78436735 induced a strong neutralizing antibody response in nearly all participants and was well-tolerated.

Immune Response 89

Immune Response Antibody Vaccine Vaccination 89

Pharmaceutical Technology

AUGUST 15, 2022

In baseline seronegative subjects, the updated vaccine offered a superior neutralising antibody response against Omicron (BA.1) Irrespective of previous infection or age, the vaccine-induced potent neutralising antibody responses against the BA.4 1) versus the 50µg mRNA-1273 booster dose.

Vaccine 214

Vaccine Vaccination Immune Response Clinical Trials 214

Worldwide Clinical Trials

OCTOBER 14, 2024

Scientists now use cutting-edge techniques, including biological therapies that target specific immune system components and precision medicine approaches that personalize treatment plans based on a patient’s genetic profile.

Research 147

Research Clinical Trials Clinical Trials Immune Response 147

Scienmag

FEBRUARY 18, 2021

Researchers at the Ragon Institute of MGH, MIT and Harvard and Massachusetts General Hospital show that levels of specific antibodies developed in the immune response may influence COVID-19 outcomes in both children and adults.

Antibody 74

Antibody Immune Response Development Research 74

World of DTC Marketing

APRIL 11, 2021

If your body develops an immune response—the goal of vaccination—there is a possibility you may test positive on some antibody tests. Antibody tests indicate you had a previous infection and that you may have some level of protection against the virus.

Vaccine 303

Vaccine Vaccination Clinical Trials Clinical Trials 303

Worldwide Clinical Trials

OCTOBER 14, 2024

Scientists now use cutting-edge techniques, including biological therapies that target specific immune system components and precision medicine approaches that personalize treatment plans based on a patient’s genetic profile.

Research 130

Research Clinical Trials Clinical Trials Immune Response 130

Scienmag

DECEMBER 2, 2021

Peer-reviewed / Randomised Controlled Trial / People Randomised, phase 2 trial of COVID-19 booster vaccines finds seven increase immunity when given 10-12 weeks after two doses of Oxford-AstraZeneca, and six increase immunity following two doses of Pfizer-BioNTech. UK trial involving 2,878 adults […].

Immune Response 68

Immune Response Trials Antibody Vaccine 68

Pharmaceutical Technology

FEBRUARY 3, 2023

Additionally, advances in the study of broadly neutralising antibodies (bNAbs) have led to new candidates being studied in early trials. The study was done in collaboration with the United States Army Medical Research and Development Command (USAMRDC), the Thai Ministry of Health, and others.

Vaccine 294

Vaccine Vaccination Antibody Trials 294

Pharmaceutical Technology

OCTOBER 25, 2022

A human monoclonal antibody, Imfinzi attaches to the PD-L1 protein and hinders the PD-L1 interaction with the PD-1 and CD80 proteins. Imjudo is also a human monoclonal antibody and hinders cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) activity.

Protein 174

Protein Immune Response Antibody FDA Approval 174

Scienmag

MARCH 25, 2021

The largest study of its kind to date also found benefit for lactating women BOSTON – In the largest study of its kind to date, researchers at Massachusetts General Hospital, Brigham and Women’s Hospital and the Ragon Institute of MGH, MIT and Harvard have found the new mRNA COVID-19 vaccines to be highly effective in […].

Immune Response 69

Immune Response Vaccine Vaccination Antibody 69

pharmaphorum

JULY 5, 2021

The number of positive cases per 100,000 people, yes/no results on PCR tests, absence or presence of antibodies – these have set the benchmarks used to determine when we can open our schools and restaurants, remove our masks and resume something resembling our old routines. As the U.S.

Immune Response 105

Immune Response Antibody Vaccine Vaccination 105

BioSpace

FEBRUARY 4, 2021

A new study report in Science suggests SARS-CoV-2 and its mutated new variants can evade immune responses via the selective deletion of small sections of the virus’s genetic sequence.

Immune Response 89

Immune Response Antibody Genetics 89

Medical Xpress

MARCH 6, 2023

A clinical trial testing a freeze-dried, temperature-stable experimental tuberculosis (TB) vaccine in healthy adults found that it was safe and stimulated both antibodies and responses from the cellular arm of the immune system.

Immune Response 74

Immune Response Vaccine Vaccination Trials 74

XTalks

DECEMBER 20, 2024

Importantly, patients switching from Stelara to Steqeyma maintained stable anti-drug antibody (ADA) levels, demonstrating consistent immune responses to the drug over time. By blocking these inflammatory pathways, it helps manage overactive immune responses in conditions like psoriasis and Crohns disease.

FDA Approval 52

FDA Approval Immune Response Antibody Marketing 52

The Pharma Data

AUGUST 16, 2021

Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV.

Immune Response 52

Immune Response Vaccine Vaccination Antibody 52

pharmaphorum

FEBRUARY 25, 2021

A nasal delivery method will also produce an immune response at the point where the virus enters the body. Altimmune’s AdCOVID is an adenovirus-vector vaccine designed to stimulate a broad immune response including both antibody and T-cell responses in the nasal cavity and respiratory tract, the point of entry for the virus.

Vaccine 111

Vaccine Vaccination Immune Response Trials 111

Pharmaceutical Technology

JANUARY 9, 2023

AbbVie has entered a global collaboration and option agreement with Immunome to discover new antibody-target pairs for cancer treatment. The multi-year collaboration will use Immunome’s Discovery Engine to discover up to ten new antibody pairs arising from three specified types of tumours.

Engineer 130

Engineer Antibody Drugs Immune Response 130

Pharmaceutical Technology

APRIL 5, 2023

Initially, the company will use its reverse immunology technology to search the database for antibodies from patients showing strong immune responses. It will then computationally re-assemble antigen-antibody pairs as potential starting points for the development of drugs.

Development 130

Development Bioinformatics Drugs Immune Response 130

NY Times

MAY 11, 2022

Antibody levels rose in the children who received it, suggesting the vaccine protects against infection. But the data were gathered before the arrival of Omicron.

Immune Response 62

Immune Response Vaccine Vaccination Antibody 62